What they share
Tesamorelin and sermorelin are both discussed as GHRH-pathway options because they stimulate endogenous growth-hormone signaling rather than directly replacing growth hormone. Because the pituitary's own feedback mechanisms stay intact, the body continues to regulate GH output through its normal negative-feedback loops — a meaningful distinction from exogenous GH administration. That shared mechanism is why clinicians often review IGF-1, metabolic history, treatment goals, and whether a GH-axis discussion is appropriate at all.
The fact that they share an axis does not mean they carry the same evidence weight, indication context, or best-fit use case.
How the two peptides differ structurally
Sermorelin is a 29-amino-acid peptide corresponding to the shortest active fragment of endogenous growth-hormone-releasing hormone (GHRH 1-29). It binds GHRH receptors on the anterior pituitary and stimulates GH synthesis and release. It was studied through the late 1990s and early 2000s (the branded product Geref was later discontinued for commercial rather than safety reasons) and is now available only as a compounded medication prepared to order at state-licensed 503A pharmacies under a clinician's prescription.
Tesamorelin is a 44-amino-acid GHRH analog — the full GHRH(1-44) sequence with a trans-3-hexenoic acid modification at the N-terminus. That modification increases its half-life and binding stability compared with native GHRH and with sermorelin's shorter fragment, which gives it a different pharmacokinetic profile. Head-to-head comparison data between the two peptides in healthy adults remains limited.
| Feature | Sermorelin | Tesamorelin |
|---|---|---|
| Peptide length | 29 amino acids (GHRH 1-29) | 44 amino acids (modified GHRH 1-44) |
| Mechanism | Stimulates pituitary GH release | Stimulates pituitary GH release |
| Half-life | Shorter (minutes) | Longer, due to the N-terminal modification |
| Randomized trial data for visceral fat | Limited in healthy adults | Multiple randomized trials in a specific population |
| Original clinical investigation | Pediatric and adult GH deficiency; pituitary testing | HIV-associated lipodystrophy |
| Branded product status | Discontinued (Geref) | FDA-approved as Egrifta SV for a specific indication |
| Compounded availability | Yes, via 503A pharmacies | Yes, via 503A pharmacies |
| Administration | Subcutaneous injection | Subcutaneous injection |
Where tesamorelin has the clearest evidence
Tesamorelin has the stronger regulatory and trial record. The active ingredient is FDA-approved as Egrifta SV for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, and that approval is built on direct visceral-fat imaging data in a specific clinical population. The pivotal randomized trial (Falutz et al., 2007) reported statistically significant trunk-fat reductions, follow-on data from the same program showed the effect was sustained over 52 weeks, and later work examined liver-fat fraction in participants with fatty liver at baseline (see the references below).
That does not automatically make tesamorelin the right choice for every body-composition conversation. It does mean claims should stay anchored to the narrower approved context and not get stretched into broad consumer promises.
Where sermorelin usually enters the discussion
Sermorelin is more often discussed as a general GH-axis option in recovery, sleep, and body-composition conversations. Its research history spans pediatric and adult GH deficiency, diagnostic pituitary testing, and age-related GH decline; the studies are longer-standing but smaller and less standardized than tesamorelin's modern, indication-specific trial program. Older studies in adults observed increases in GH secretion and IGF-1, but the endpoints were hormonal rather than body-compositional.
A fair comparison is not 'stronger versus weaker' in the abstract. It is whether the question is really about targeted visceral-fat evidence, or about a broader clinician-guided GH-axis discussion with different expectations and follow-up needs.
Who each peptide has been studied in
Tesamorelin's trial populations have been predominantly adults living with HIV who had excess visceral adiposity — a narrow but deep research focus with multiple randomized controlled trials and long-term extension studies. Sermorelin's populations are more varied, but the individual studies tend to be smaller and older.
Neither peptide has been extensively studied in healthy, young adults seeking performance enhancement. That is an honest limitation worth acknowledging before either option is discussed, and it is why the available evidence should be contextualized by a licensed clinician against your own goals and history.
Compounded versions versus the branded product
When either peptide is obtained through a telehealth platform such as New Blue Health, it is compounded to order at a state-licensed 503A pharmacy pursuant to an individual prescription. Compounded medications are prepared to order, not commercially manufactured, and they are not evaluated through the same regulatory review process as commercially manufactured drugs. The branded tesamorelin product's approval applies to a specific formulation and indication; that status does not extend to compounded formulations or off-label uses.
New Blue Health publishes a compounding and off-label disclosure that describes the sourcing and oversight framework for its pharmacy partners. Patients should understand the distinction, and a licensed clinician should explain it during the consultation.
Safety considerations
Both peptides are generally well tolerated in published studies, but neither is without risk. Commonly reported side effects include injection-site reactions (redness, swelling, pain), headache, and transient flushing. Because both increase GH secretion, they carry theoretical risks associated with elevated GH and IGF-1 — joint pain, fluid retention, and carpal-tunnel-like symptoms — which are typically dose-dependent and reversible.
The branded tesamorelin prescribing information lists contraindications including active malignancy, pregnancy, and disruption of the hypothalamic-pituitary axis. Long-term safety data for compounded GHRH analogs in healthy adults is limited, which is a reason to work with a clinician who screens for contraindications and monitors response over time rather than simply writing a prescription.
Questions to review before choosing or switching
- What is the actual treatment goal: visceral-fat reduction, broader body composition, recovery, or sleep?
- What evidence level supports this discussion, and how narrow is the approved indication?
- What monitoring will change if IGF-1 or glucose becomes a concern?
- Is this comparison happening calmly, or because of access pressure, pricing stress, or a recent plateau?
- Would starting with one cleaner discussion be safer than combining multiple pathways?
When this is not really a peptide comparison
Sometimes patients ask 'tesamorelin or sermorelin' when the real issue is something else: inconsistent recovery habits, plateau frustration, GLP-1 sequencing, unclear labs, or a desire for a body-composition shortcut. That is why the next step should be clinician review rather than assuming either option is the answer.
Frequently asked questions
Is sermorelin the same as tesamorelin?
No. Both are growth-hormone-releasing hormone (GHRH) analogs that stimulate the pituitary to produce growth hormone, but they differ in peptide structure, half-life, and the clinical research behind them. Tesamorelin has more robust randomized controlled trial data, particularly for visceral-fat reduction in a specific population. A licensed clinician can help determine which, if either, may be appropriate for your goals.
What is the regulatory status of compounded sermorelin and tesamorelin?
Compounded versions of both peptides are prepared at state-licensed 503A compounding pharmacies under a clinician's prescription and are not commercially manufactured drug products. The branded form of tesamorelin (Egrifta SV) is FDA-approved for a specific indication, but that status does not extend to compounded formulations or off-label uses.
How do I know which peptide is right for me?
Eligibility depends on clinical review. A licensed clinician evaluates your health history, lab work, and goals to determine whether a growth-hormone peptide pathway — and which specific peptide — may be appropriate. New Blue Health is a technology and administrative services platform, not a medical provider; all medical decisions are made by independent licensed clinicians, and not everyone qualifies.
Does the consultation cost extra on top of the pathway price?
No. New Blue Health pathways are priced all-in, with the clinical consultation included; current prices and term options are shown on the tesamorelin and sermorelin treatment guides. If a clinician determines that a prescription is not appropriate, the medication cost is refunded; the consultation terms are set out in the refund policy.
References
- DailyMed: Egrifta SV (tesamorelin) prescribing information — Official product labeling for the FDA-approved tesamorelin indication, including contraindications.
- PubMed: Tesamorelin treatment of excess abdominal fat in HIV-associated lipodystrophy — Foundational randomized clinical data supporting the approved tesamorelin context.
- PubMed: Tesamorelin and liver fat in HIV and NAFLD — Often cited when clinicians review broader metabolic context and evidence limits.
Related reading
Risk, contraindications, interactions, and follow-up planning should be reviewed before initiating any peptide pathway.
This content is educational and does not replace individualized medical advice. Treatment decisions should be made with a licensed clinician based on personal history, risk profile, and appropriate monitoring. New Blue Health is a technology and administrative services platform, not a medical provider.